Anti-endoglin antibodies and knockin mice expressing novel human/mouse chimeric endoglin
AssigneeHealth Research, Inc.
InventorsBen K. Seon, Hirofumi Toi
Life of this patent
Estimating the term…
Loading patent…
AssigneeHealth Research, Inc.
InventorsBen K. Seon, Hirofumi Toi
Estimating the term…
Provided are compositions and methods that relate to prophylaxis and therapy of angiogenesis associated disease and includes novel knockin mice which express novel human/mouse chimeric endoglin, vectors for use in making such mice, and murine embryonic stem cells comprising the novel human/mouse transgene. Also provided are anti-human endoglin monoclonal antibodies (mAbs) which can be used as antiangiogenic agents for prophylaxis or therapy of human tumor angiogenesis and human angiogenesis-associated diseases having excessive vascularization. The mAbs do not cross react with murine endoglin. Also provides are methods for using the anti-human endoglin mAbs for prophylaxis or therapy of human tumor angiogenesis and for angiogenesis-associated diseases having excessive vascularization.
An isolated antibody or a fragment thereof, wherein the antibody or fragment thereof binds with specificity to a region of human endoglin between human endoglin amino acid Asn 121 and amino acid Ala 378, wherein the region of human endoglin between human endoglin amino acid Asn 121 and amino acid Ala 378 comprises the sequence of SEQ ID NO:9, and wherein the antibody is not cross-reactive with murine endoglin.
Dependencies are inferred from the claim text.